Abstract
The pharmacokinetics of orally administered ticlopidine hydrochloride, a novel inhibitor of platelet aggregation, were determined both after a single dose and after 21 days of twice daily dosing in 12 young (mean 28.6 years) and 13 elderly (mean 69.5 years) subjects. Concentrations of unchanged ticlopidine in plasma were measured by g.l.c. After a single 250 mg dose of ticlopidine, the mean area under the curve, AUC (0-12 h) was 1.11 micrograms ml-1 h in young subjects and 2.04 micrograms ml-1 h in old subjects (P = 0.002). Mean values of t1/2,z in young and elderly subjects were 7.9 h and 12.6 h, respectively (P = 0.01). Steady state plasma drug concentrations were attained after 14 days of dosing with ticlopidine. After the final dose on day 21, AUC values in elderly subjects were 2-3 times those in young subjects (P less than 0.001). The plasma t1/2,z averaged 4.0 days for young subjects and 3.8 days for elderly subjects (P = 0.7). The longer t1/2,z and higher AUC values after multiple dosing probably reflect an increase in bioavailability of ticlopidine after repeated dosing, saturation of metabolism or insufficient analytical sensitivity to characterize the terminal elimination phase after single dose.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Féliste R., Delebassée D., Simon M. F., Chap H., Defreyn G., Vallée E., Douste-Blazy L., Maffrand J. P. Broad spectrum anti-platelet activity of ticlopidine and PCR 4099 involves the suppression of the effects of released ADP. Thromb Res. 1987 Nov 15;48(4):403–415. doi: 10.1016/0049-3848(87)90398-7. [DOI] [PubMed] [Google Scholar]
- Gent M., Blakely J. A., Easton J. D., Ellis D. J., Hachinski V. C., Harbison J. W., Panak E., Roberts R. S., Sicurella J., Turpie A. G. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Design, organization, and baseline results. Stroke. 1988 Oct;19(10):1203–1210. doi: 10.1161/01.str.19.10.1203. [DOI] [PubMed] [Google Scholar]
- Glasson S., Zini R., Tillement J. P. Multiple human serum binding of two thienopyridinic derivatives, ticlopidine and PCR 2362, and their distribution between HSA, alpha1-acid glycoprotein and lipoproteins. Biochem Pharmacol. 1982 Mar 1;31(5):831–835. doi: 10.1016/0006-2952(82)90470-1. [DOI] [PubMed] [Google Scholar]
- Hass W. K., Easton J. D., Adams H. P., Jr, Pryse-Phillips W., Molony B. A., Anderson S., Kamm B. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med. 1989 Aug 24;321(8):501–507. doi: 10.1056/NEJM198908243210804. [DOI] [PubMed] [Google Scholar]
- Knudsen J. B., Gormsen J. The effect of ticlopidine on platelet function in normal volunteers and in patients with platelet hyperaggregability in vitro. Thromb Res. 1979;16(5-6):663–671. doi: 10.1016/0049-3848(79)90210-x. [DOI] [PubMed] [Google Scholar]
- Panak E., Maffrand J. P., Picard-Fraire C., Vallée E., Blanchard J., Roncucci R. Ticlopidine: a promise for the prevention and treatment of thrombosis and its complications. Haemostasis. 1983;13 (Suppl 1):1–54. doi: 10.1159/000214831. [DOI] [PubMed] [Google Scholar]
- Picard-Fraire C. Pharmacokinetic and metabolic characteristics of ticlopidine in relation to its inhibitory properties on platelet function. Agents Actions Suppl. 1984;15:68–75. [PubMed] [Google Scholar]
- Shand D. G. Biological determinants of altered pharmacokinetics in the elderly. Gerontology. 1982;28 (Suppl 1):8–17. doi: 10.1159/000212568. [DOI] [PubMed] [Google Scholar]
- Vestal R. E. Drug use in the elderly: a review of problems and special considerations. Drugs. 1978 Oct;16(4):358–382. doi: 10.2165/00003495-197816040-00004. [DOI] [PubMed] [Google Scholar]